Stem cells used to build bone and fight cancerMedical XpressHyunwoo "Paco" Kang, an orthopedic surgery resident at the Keck School of Medicine, will use stem cells to treat critical-sized bone defects, or fractures that are too large to heal … Continue reading
Journal of Clinical PathwaysManaging Treatment-Related Toxicity Identified as an Educational Need in ImmunotherapyJournal of Clinical PathwaysA recent survey presented at the ASCO-SITC Clinical Immuno-Oncology Symposium (January 25-27, 2018; San Franci… Continue reading
Journal of Clinical PathwaysTreatment-Related Toxicity Management Identified as an Educational Need in ImmunotherapyJournal of Clinical PathwaysA recent survey presented at the ASCO-SITC Clinical Immuno-Oncology Symposium (January 25-27, 2018; San Fran… Continue reading
The ScientistKyoto University Finds Stem Cell Researcher Guilty of Data FabricationThe ScientistFLICKR, JPELLGENKyoto University announced the results of an investigation into research misconduct this week (January 22), finding one of its scientists—wh… Continue reading
Scientific American |
The Pharma Exec behind the First Approved Gene Therapy Is Hunting for His Next Big Break
Scientific American Joseph Jimenez retires at the end of the month after eight years in the top job at Novartis, one of the world’s largest pharmaceutical companies. Under his leadership the company sold off its vaccine division and shifted its focus to developing generic … |
|
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in …
Business Wire (press release) PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated study … |
FierceBiotech |
Synpromics, UCL ally to aim gene therapies at blood-based diseases
FierceBiotech Synpromics has entered into another gene therapy collaboration with UCL. This time around the aim is to apply Synpromics’ synthetic promoter expertise to the development of gene therapies against diseases affecting blood production. Working with Adrian … Synpromics Announces New Partnership with UCL to Develop …Business Wire (press release) Gene therapy developer Synpromics signs collaboration deal …insider.co.uk Collaboration formed for development of novel gene therapies for …EPM Magazine |
PMLiVE |
Novartis negotiates ex-US rights to Spark gene therapy
PMLiVE Novartis has agreed to develop Spark Therapeutics’ recently-approved gene therapy Luxturna outside the US, in a deal valued at $170m. The Swiss pharma group is paying $105m for ex-US rights to Luxturna (voretigene neparvovec-rzyl), which is currently … |